![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, March 08, 2020 7:35:39 PM
GlobeNewswire GlobeNewswire•March 6, 2020
San Diego, California, March 06, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences company that develops, formulates, manufacture and distributes condition-specific medical foods supported by evidence-based protocols, today announced that it has received total gross proceeds of $3,510,630.00 during the period from February 28, 2020 through March 3, 2020 from the exercise of 10,265,000 warrants issued in the Company’s October 2019 follow-on offering at an exercise price of $0.342 per share.
Proceeds from exercise of the warrants are being utilized to fund Guardion’s efforts to develop new products, market and distribute both existing and new products, and for working capital and general corporate purposes.
The Company has approximately 85,247,562 common shares currently issued and outstanding.
“We are pleased with the participation of our shareholders and are grateful for their continued support,” commented Michael Favish, CEO of Guardion. “Building on this momentum, we expect to increase awareness of our existing products through a robust marketing effort, while working to develop new products to add to our growing portfolio.”
About Guardion Health Sciences, Inc.
Guardion® is an ocular health sciences company that develops, formulates, manufacture and distributes condition-specific medical foods supported by evidence-based protocols. Guardion’s initial medical food product, Lumega-Z, addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”) and a significant component of functional vision performance. Guardion has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov.
About VectorVision®
VectorVision® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision’s® patented technology is considered the standard of care for clinical trials. VectorVision® is a wholly owned subsidiary of Guardion.
Guardion has completed development of the proprietary VectorVision® CSV-2000 standardized contrast sensitivity test and recently introduced the commercial product to the marketplace. The CSV-2000 is the only computer-generated vision testing instrument available that will provide the optical marketplace with the Company’s proprietary, industry-standard contrast sensitivity test, along with a full suite of standard vision testing protocols. The proprietary standardization methodology incorporated into the CSV-2000 includes a patented technology known as AcQviz that automatically and constantly measures and adjusts screen luminance to a fixed standard light level for vision testing.
About NutriGuardTM
NutriGuardTM formulates high-quality, scientifically credible nutraceuticals, which are designed to supplement consumers’ diets and assist in the prevention and management of an array of diseases and conditions. NutriGuard uses pharmaceutical standards to establish the safety and efficacy of the products it develops and markets, and also maintains that commitment through rigorous manufacturing and quality assurance programs. Guardion plans to increase NutriGuard’s existing customer base and build on its product platform by making NutriGuard products available to patients directly and through recommendations by their physicians.
Recent GHSI News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:11:41 PM
- Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor’s Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution • GlobeNewswire Inc. • 05/31/2024 08:33:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/23/2024 08:56:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:54:41 PM
- Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business • GlobeNewswire Inc. • 05/23/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 12:05:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/21/2024 12:05:14 PM
- Guardion Health Sciences Announces its Largest Stockholder Has Voted in Favor of Proposals to Sell the Viactiv Business and the Liquidation Plan at the Company’s Special Meeting of Stockholders to be held on May 23, 2024 • GlobeNewswire Inc. • 05/21/2024 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/15/2024 12:42:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:39:34 PM
- Guardion Health Sciences Announces • GlobeNewswire Inc. • 05/13/2024 09:01:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:46:01 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 08:01:37 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2024 04:15:26 AM
- Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023 • GlobeNewswire Inc. • 03/29/2024 10:15:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:19:56 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 01/31/2024 10:21:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:18:13 PM
- Guardion Health Sciences Announces Entry into Definitive Agreement to Sell its Well-Known Viactiv® Brand and Business to Doctor’s Best Inc. • GlobeNewswire Inc. • 01/30/2024 11:13:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:15:26 PM
- Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2023 • GlobeNewswire Inc. • 11/13/2023 09:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:05:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 08:30:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:48:46 PM
- Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023 • GlobeNewswire Inc. • 08/14/2023 12:15:00 PM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM